167 related articles for article (PubMed ID: 25421283)
1. Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery.
Gao Q; Wang XY; Zhou J; Fan J
Nat Rev Clin Oncol; 2015 Jan; 12(1):10. PubMed ID: 25421283
[No Abstract] [Full Text] [Related]
2. Reply: Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery.
Forner A; Gilabert M; Bruix J; Raoul JL
Nat Rev Clin Oncol; 2015 Jan; 12(1):10. PubMed ID: 25421282
[No Abstract] [Full Text] [Related]
3. Intermediate-stage HCC--upfront resection can be feasible.
Forner A; Gilabert M; Bruix J; Raoul JL
Nat Rev Clin Oncol; 2015 May; 12(5):. PubMed ID: 25850552
[No Abstract] [Full Text] [Related]
4. Intermediate-stage HCC--upfront resection can be feasible.
Zhong JH; Lu SD; Wang YY; Ma L; Li LQ
Nat Rev Clin Oncol; 2015 May; 12(5):. PubMed ID: 25850549
[No Abstract] [Full Text] [Related]
5. Transarterial chemoembolization for hepatocellular carcinoma.
Lau WY; Yu SC; Lai EC; Leung TW
J Am Coll Surg; 2006 Jan; 202(1):155-68. PubMed ID: 16377509
[No Abstract] [Full Text] [Related]
6. Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment.
Tsochatzis EA; Germani G; Burroughs AK
Semin Oncol; 2010 Apr; 37(2):89-93. PubMed ID: 20494700
[TBL] [Abstract][Full Text] [Related]
7. Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?
Sacco R; Antonucci M; Bargellini I; Marceglia S; Mismas V; Cabibbo G
Future Oncol; 2015; 11(17):2371-3. PubMed ID: 26270206
[No Abstract] [Full Text] [Related]
8. Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy.
Lencioni R
Crit Rev Oncol Hematol; 2012 Aug; 83(2):216-24. PubMed ID: 22142656
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.
Bolondi L; Burroughs A; Dufour JF; Galle PR; Mazzaferro V; Piscaglia F; Raoul JL; Sangro B
Semin Liver Dis; 2012 Nov; 32(4):348-59. PubMed ID: 23397536
[TBL] [Abstract][Full Text] [Related]
10. Transcatheter arterial chemoembolization combined with radiofrequency ablation for the treatment of hepatocellular carcinoma.
Peng ZW; Chen MS
Oncology; 2013; 84 Suppl 1():40-3. PubMed ID: 23428857
[TBL] [Abstract][Full Text] [Related]
11. Regional chemotherapy and transcatheter arterial chemoembolization.
Gallkowski U; Low A; Hirner A
Digestion; 1998 Jul; 59 Suppl 2():83-5. PubMed ID: 9718432
[No Abstract] [Full Text] [Related]
12. Transarterial Chemoembolization and (90)Y Radioembolization for Hepatocellular Carcinoma: Review of Current Applications Beyond Intermediate-Stage Disease.
Fidelman N; Kerlan RK
AJR Am J Roentgenol; 2015 Oct; 205(4):742-52. PubMed ID: 26397322
[TBL] [Abstract][Full Text] [Related]
13. Non-surgical treatment of hepatocellular carcinoma (HCC).
Fevery J
Acta Gastroenterol Belg; 2000; 63(2):233-5. PubMed ID: 10925476
[No Abstract] [Full Text] [Related]
14. [Interventional therapy for hepatocellular carcinoma].
Wang JH
Zhonghua Gan Zang Bing Za Zhi; 2005 Oct; 13(10):721-3. PubMed ID: 16248940
[No Abstract] [Full Text] [Related]
15. Management of hepatocellular carcinoma in human immunodeficiency virus-infected patients.
Bruno R; Puoti M; Sacchi P; Filice C; Carosi G; Filice G
J Hepatol; 2006; 44(1 Suppl):S146-50. PubMed ID: 16356582
[TBL] [Abstract][Full Text] [Related]
16. Use of PhaSeal transfer system during chemoembolization to prevent unintentional leakage of chemotherapeutic agents during preparation and delivery.
Contractor S; Kumar A; Phillip M; Patel D; Karcich J; Kisza P
J Vasc Interv Radiol; 2015 Jan; 26(1):137-9. PubMed ID: 25541453
[No Abstract] [Full Text] [Related]
17. TACE it or leave it: hard choices for intermediate-stage hepatocellular carcinoma patients beyond perfect health.
Peck-Radosavljevic M
Liver Int; 2010 Jan; 30(1):3-4. PubMed ID: 19929902
[No Abstract] [Full Text] [Related]
18. Re: Safety and Efficacy of 70-150 µm and 100-300 µm Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma.
Tu J; Jia Z; Jiang G
J Vasc Interv Radiol; 2015 Aug; 26(8):1251. PubMed ID: 26210251
[No Abstract] [Full Text] [Related]
19. Transarterial chemoembolization and sorafenib in hepatocellular carcinoma.
Cabibbo G; Tremosini S; Galati G; Mazza G; Gadaleta-Caldarola G; Lombardi G; Antonucci M; Sacco R
Expert Rev Anticancer Ther; 2014 Jul; 14(7):831-45. PubMed ID: 24850249
[TBL] [Abstract][Full Text] [Related]
20. Vascular complications of hepatic artery after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
Sueyoshi E; Hayashida T; Sakamoto I; Uetani M
AJR Am J Roentgenol; 2010 Jul; 195(1):245-51. PubMed ID: 20566824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
